ATI-105
/ Adjuvia Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 10, 2026
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Adjuvia Therapeutics, Inc.
New P1 trial • Ataxia • Cardiomyopathy • CNS Disorders • Friedreich ataxia • Genetic Disorders • Metabolic Disorders • Movement Disorders
1 to 1
Of
1
Go to page
1